Novo Nordisk partners with Vivtex on $2.1B deal to develop oral diabetes and obesity drugs using advanced delivery tech.

Danish drugmaker Novo Nordisk has partnered with U.S. biotech Vivtex in a deal potentially worth $2.1 billion to develop oral versions of biologic drugs for obesity and diabetes. The collaboration leverages Vivtex’s advanced drug-delivery technology, including AI and gut-screening systems, to improve how large molecules like semaglutide are absorbed in the digestive tract. Novo will lead global development and commercialization, aiming to overcome the limitations of injectable treatments. The partnership supports Novo’s strategy to expand its oral GLP-1 therapies, following the 2025 FDA approval of oral Wegovy and the launch of oral Ozempic. Financial terms include upfront payments, milestones, and royalties, though specifics were not disclosed.